Saturday, August 2, 2025

Latest

Bright Minds Bioscience Approved For Nasdaq Listing

There’s another Canadian firm set to trade on the Nasdaq market. Bright Minds Bioscience (CSE: DRUG) this morning announced that it has been approved to begin trading on the major big board exchange.

The company will see its equity begin trading on the major US exchange as of November 8, where it will trade under the symbol “DRUG”, similar to its listing here in Canada. The firm will remain dual listed, with the move to not affect its listing on the Canadian Securities Exchange.

“Our listing on Nasdaq marks an important corporate milestone for Bright Minds, as we continue to advance our innovative drug candidates in pursuit of an improved generation of targeted serotonin-based therapies,” commented Ian McDonald, CEO of Bright Minds.

In making the announcement, McDonald identified that the move was made as it works to provide further liquidity for its shareholders, with the Nasdaq being the most liquid exchange globally.

Bright Minds is currently focused on developing novel psychedelic-based drugs for the targeted treatment of pain, epilepsy, and neuropsychiatric disorders. The firm is pushing towards in-human trials for BMB-101, it’s lead drug candidate, which focuses on the treatment of Dravet syndrome. Trials are expected to begin in the first half of 2022.

Bright Minds Bioscience last traded at $9.00 on the CSE.


FULL DISCLOSURE: Bright Minds Biosciences is a client of Canacom Group, the parent company of The Deep Dive. The company has been compensated to cover Bright Minds Biosciences on The Deep Dive, with The Deep Dive having full editorial control. Not a recommendation to buy or sell. Always do additional research and consult a professional before purchasing a security.

One Response

Video Articles

Why Gold’s Bull Run May Just Be Getting Started! | Peter Grandich

Tariffs Spark New Race for Critical Metals | Rob McEwen

Antimony Resources: The Bald Hill Project

Recommended

Tsunami Warnings Spread As Largest Quake Since 2011 Hits Russia

Northern Superior Intersects 1.75 g/t Gold Over 65.0 Metres At Philibert

Related News

Explainer: Anti Alzheimer’s, Dravet Syndrome, Epilepsy & Addiction Drugs – The Daily Dive

On today’s Daily Dive, Cassandra welcomes back Ian McDonald, CEO of Bright Minds Biosciences (CSE:...

Friday, September 10, 2021, 01:30:00 PM

Bright Minds Biosciences Looks To Raise $4.0 Million Via Overnight Offering

After several days of intense volatility, Bright Minds Biosciences (CSE: DRUG) is looking to capitalize...

Wednesday, August 24, 2022, 08:40:23 AM

Bright Minds Biosciences: Corporate Overview

Bright Minds Biosciences Inc. (CSE: DRUG) is a small-cap preclinical biosciences company that is attempting to...

Monday, May 31, 2021, 02:43:00 PM

Bright Minds: Focusing On Second Generation Psychedelic Compounds – The Daily Dive

Starting off this week on the Daily Dive is that of Dr Gideon Shapiro, whom...

Monday, June 21, 2021, 01:30:00 PM

Bright Minds Expands Leadership, Scientific Advisory Teams

Bright Minds Biosciences (CSE: DRUG) this morning enhanced its leadership team. The company appointed two...

Tuesday, April 27, 2021, 08:44:04 AM